Lyduine Collij, PhD, BioFINDER group, Lund University, Lund, Sweden, discusses our current understanding of blood-based tau biomarkers, highlighting research that shows many p-tau variants are likely to be more reflective of amyloid pathology than tau burden. The strong correlation between tau burden and cognition is well recognized. It is therefore important to establish cost effective and accessible biomarkers that are more specific for tau. Dr Collij mentions ongoing research into p-tau205 and MTBR-243 as markers of tau pathology. This interview took place at the CTAD 2023 conference in Boston, MA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.